Adapalene gel 0.3% for the treatment of acne vulgaris: A multicenter, randomized, double-blind, controlled, phase III trial Diane Thiboutot, MD, David.

Slides:

Advertisements

Similar presentations

Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Adapalene Gel, 0.1%, as Maintenance Therapy for Acne.

Advertisements

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

Striking leflunomide efficacy against refractory cutaneous sarcoidosis

A randomized controlled crossover trial: Lidocaine injected at a 90-degree angle causes less pain than lidocaine injected at a 45-degree angle Kathryn.

The impact of chocolate consumption on acne vulgaris in college students: A randomized crossover study Gregory R. Delost, DO, Maria E. Delost, PhD, Jenifer.

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Thomas B. Casale, MD, Patrick H. Win, MD, Jonathan A

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Surveillance and assessment of occupational dermatitis using Rhode Island workers' compensation data 1998 to 2002 Irwin B. Horwitz, PhD, Brian P. McCall,

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault,

A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced.

A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB.

Brad A. Yentzer, MD, Ali Alikhan, BS, Hoa Teuschler, MS, Lisa L

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis Alice B. Gottlieb, MD, PhD,

Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection Alberto Conde-Taboada, MD, Javier Pedraz Muñoz, MD, Lucía.

A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies Linda.

Reply to: “Comment on ‘Activation of melanocytes in idiopathic guttate hypomelanosis after 5-fluorouracil infusion using a tattoo machine: Preliminary.

Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled.

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Topical calcipotriol before ablative fractional laser-assisted photodynamic therapy enhances treatment outcomes for actinic keratosis in Fitzpatrick grades.

Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind,

Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial Lauren Okon, MD, Misha Rosenbach, MD, Michael.

Ethan T. Routt, BA, Jacob O. Levitt, MD

Lip edema Journal of the American Academy of Dermatology

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Acne fulminans successfully treated with cyclosporine and isotretinoin

Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants Roland Kaufmann, MD, Regina Fölster-Holst, MD, Peter Höger, MD,

A comparison of postprocedural wound care treatments: Do antibiotic-based ointments improve outcomes? Zoe D. Draelos, MD, FAAD, Ronald L. Rizer, PhD,

Medicaid acceptance among pediatric dermatologists

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial Sonja Ständer, MD, Paul Kwon, MD,

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3.

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Modification of the nail psoriasis severity index

Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled.

Tofacitinib therapy for children with severe alopecia areata

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.

Jose Fernández-Vozmediano, PhD, Jose Armario-Hita, MD

Postprocedural wound-healing efficacy following removal of dermatosis papulosa nigra lesions in an African American population: A comparison of a skin.

Descriptive survival study of nail melanoma patients treated with functional surgery versus distal amputation Suelen Montagner, MD, Francisco Aparecido.

Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Gaps in pain management in dermatology: A needs assessment from Canada

Alan Menter, MD, Stephen K

Efficacy and safety of oxymetazoline cream 1

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne Jerry Tan, MD, Diane Thiboutot, MD, Georg Popp,

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Orit Kaidar-Person, MD, Ayelet Eran, MD, Gil Bar-Sela, MD

Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment Michael.

Stuart M. Goldsmith, MD, Armand B. Cognetta, MD

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase.

Presentation transcript:

Adapalene gel 0.3% for the treatment of acne vulgaris: A multicenter, randomized, double-blind, controlled, phase III trial Diane Thiboutot, MD, David M. Pariser, MD, FACP, Nancy Egan, MD, Javier Flores, MD, James H. Herndon, MD, Norman B. Kanof, MD, Steven E. Kempers, MD, Stuart Maddin, MD, FRCPC, Yves P. Poulin, MD, David C. Wilson, MD, DCH, FRCP(Ed), FRCPCH, Joyce Hwa, Yin Liu, PhD, Michael Graeber, MD Journal of the American Academy of Dermatology Volume 54, Issue 2, Pages 242-250 (February 2006) DOI: 10.1016/j.jaad.2004.10.879 Copyright © 2006 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Patient disposition. ITT, Intent to treat; PP, per protocol. Journal of the American Academy of Dermatology 2006 54, 242-250DOI: (10.1016/j.jaad.2004.10.879) Copyright © 2006 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Total lesion count. CMH, Cochran-Mantel-Haenszel; GEE, generalized estimating equation. ∗CMH test: at least P < .05 for adapalene gel 0.3% versus gel vehicle. ∗∗CMH test: at least P < .05 for adapalene gel 0.3% versus adapalene gel 0.1% and adapalene gel 0.3% versus gel vehicle. †GEE analysis P = .02 for adapalene gel 0.3% versus adapalene gel 0.1% and P = .005 for adapalene gel 0.3% versus gel vehicle based on week 8 and week 12 data. Journal of the American Academy of Dermatology 2006 54, 242-250DOI: (10.1016/j.jaad.2004.10.879) Copyright © 2006 American Academy of Dermatology, Inc. Terms and Conditions

Fig 3 Effect of adapalene gel 0.3% on facial lesions at baseline and after 4, 8, and 12 weeks of treatment. Journal of the American Academy of Dermatology 2006 54, 242-250DOI: (10.1016/j.jaad.2004.10.879) Copyright © 2006 American Academy of Dermatology, Inc. Terms and Conditions

Fig 4 Local tolerability. Effects of adapalene gel 0.3% versus adapalane gel 0.1% and gel vehicle on mean scores for skin tolerance variables: erythema (A), scaling (B), dryness (C), and stinging/burning (D). Skin tolerability variables were assessed according to following scoring scale: none = 0, mild = 1, moderate = 2, and severe = 3. Mean scores at each postbaseline visit and worst score (worst observation recorded for patient during postbaseline period) are included. Journal of the American Academy of Dermatology 2006 54, 242-250DOI: (10.1016/j.jaad.2004.10.879) Copyright © 2006 American Academy of Dermatology, Inc. Terms and Conditions